BioSpace News Archive

Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced it will host a virtual R&D and Investor Day on Wednesday, June 14, 2023 at 1:00 PM ET.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.

InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV) today announced that Patrick Blair, president and CEO, and Barbara Gutierrez, CFO will be speaking at the 44th Annual Goldman Sachs Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. (PT) / 12:20 p.m. (ET).

Vor Bio, a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sachs 44th Annual Global Healthcare Conference.

Rani Therapeutics Holdings, Inc. announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar.

Replimune Group, Inc. (Nasdaq: REPL) today announced the appointment of Veleka R. Peeples-Dyer to the Company’s Board of Directors effective June 1, 2023.

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the completion of the dose-escalation portion of the Phase 1/2a study for its lead asset IMM-1-104 in patients with advanced solid tumors.

Amolyt Pharma today announced the initiation of a Phase 1 clinical trial of the Company’s peptide growth hormone receptor antagonist (GHRA), AZP-3813, which is being developed as a potential add-on to somatostatin analogs (SSAs) for the treatment of acromegaly.

NKGen Biotech Inc. (NKGen) today announced a poster presentation of preclinical and Phase I/IIa clinical data by its parent company, NKMax Co., Ltd. (NKMax).

Morphogenesis, Inc. and CohBar, Inc., announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.